

No
6
20
20.1
31
31.1
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
107.1
107.2
108
109
110
111
113.1
366
367
115
116
117
118
119
120

121
122
123
124
125
126
126.1
126.2
127
128
129
129.1
130
130.1
130.2
131
131.1
132
133
133.1
134
135
136
136.1
137
140
141
143
158
163
164
165
167
169
170
171
172
173
176
177

178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
213
214
215
216
217
218
218.1
219
220
221
222
223
224

225
226
227
228
229
229.1
230
231
232
233
234
235
236
237
237.1
238
239
240
241
241.1
242
243
244
245
246
247
248
249
250
251
251.1
252
253
254
255

261
262
263
264
265
266
267
268
269
270

270.1
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
304
305
306
307
308
308.1
309
309.1
310
310.1
311

311.1
312
313
313.1
314
315
315.1
316
317
318
319
320
321
322
323
324
324.1
325
326
327
328
329
330
330.2
330.3
331
331.1
332
333
334
335
336
337
338

339
340
341
342
343
344
345
346
346.1
346.2

347
348
349
350
351
352
353
353.1
354
355
356
357
358
359
360
361
362
363
364
365

**GESTDEM 2020/5436 and GESTDEM 2021/0559 FOURTH BATCH**

/5436 and GESTDEM 2021/0559 FOURTH BATCH

**STEERING BOARD MEETINGS\_AGENDA**

Subject
Meeting 03 07 2020 – Minutes
SB Minutes_17 August 2020
pro-rata adjusted+EUROSTAT'
Email_SB Agenda_11 September 2020
Agenda_SB Minutes_11 September 2020
Scientific Presentation by AstraZeneca Representatives - 5 August 2020 - Report and Presentation
Scientific Update by Sanofi Pasteur Representatives -17 December 2020 - Report and Presentation
Scientific Update by CureVac Representatives, 17 November 2020 - Pre-Clinical and Clinical Development Data Upda
Scientific Update by CureVac Representatives, 3 November 2020 - Report and Presentation
Scientific Presentation by ReiThera Representatives, 8 October 2020 - Report and Presentation
Follow-up Discussion to the Scientific Presentation by CureVac Representatives, 7 October 2020
Scientific Presentation by CureVac Representatives, 28 September 2020 - Report and Presentation
Scientific Presentation by Sanofi-GSK Representatives, 9 September 2020 - Report and Presentation
Scientific Presentation by Johnson & Johnson Representatives, 4 September 2020 - Report and Presentation
Scientific Presentation by CureVac Representatives, 28 August 2020 - Report and Presentation
Scientific Presentation by Novavax Representatives, 11 August 2020 - Report and Presentation
Scientific Presentation by BioNTech/ Pfizer Representatives - 7 August 2020 - Report
Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 -?
Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 -
Scientific considerations regarding the adenovirus vectored vaccines against SARS-COV-2 - Opinion of the Spanish Scientific Committee
Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 - S
Steering Board Meeting with Experts from the Scientific Board of France, Spain and the Netherlands, 27 July 2020 - S
European Commission's advisory panel on COVID-19, report – videoconference 20/07/2020
European Commission's advisory panel on COVID-19, Invitation letter– videoconference 20/07/2020
European Commission's advisory panel Letter
Scientific Update by AstraZeneca Representatives - Safety and efficacy - 15 December 2020
Scientific meeting with Moderna, 15 July 2020
Overview of contacts with companies on COVID-19 vaccine presented to the Steering Board, 26.02.2021
Overview of contacts with companies on COVID-19 vaccine presented to the Steering Board, 03.11.2020
Annex_Confidentiality_SB Meeting 25 September 2020
Overview - contacts with other companies on COVID-19 vaccine presented to the Steering Board 30.07.20
Overview - contacts with other companies on COVID-19 vaccine presented to the Steering Board 14.07.20
<b>ASTRA ZENECA</b>
1. Draft APA negotiated between AstraZeneca and the Evaluation Committee on 13-08-20
2. Draft APA negotiated between AstraZeneca and EvaluationCommittee on 13-08-20 2
1.AstraZeneca COVID-19 Vaccine Update on developments sent to the European Commission
AW Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 1 (DE)
3. AW Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 2 (DE)
4. Follow up - AZ EC exploratory meeting



5. Re URGENT - info about suspension of clinical trials for COVID-19 vaccine
6. RE Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 3 (FR)
7. RE Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 4 (FR)
8. TR Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 5 (FR)
9. WG Draft Term Sheet for Supply of AstraZeneca COVID-19 vaccine (AZD 1222) in Europe - comments JNT 6 (DE)
Call for tenders SANTE/2020/C3/037 for the development, production, priority-purchasing options and supply of COVID-
Call for tenders SANTE2020C3037 for the development, production, priority-purchasing options and supply
Call for tenders SANTE2020C3037 for the development, production, priority-purchasing_Annex 6 - Financial offer
RE: CALL FOR TENDERS SANTE/2020/C3/037 – OFFER
SANTE/2020/C3/037 - Notification Letter : Call for tenders for the development, production, priority-purchasing options
Notification letter: SANTE/2020/C3/037: Development, production, priority-purchasing options and supply of
Notification letter: SANTE/2020/C3/037: Development, production, priority-purchasing options and supply of
SARS CoV-2 Vaccine (AZD1222) Progress Report 19 January 2021
FD tbcUKPAR_COVID_19_Vaccine_AstraZeneca_05.01.2021_RED
Email SARS CoV-2 Vaccine (AZD1222) Progress Report 19 January 2021
MHRA Public Assessment Report AZ Covid-19 Vaccine
FD tbc UKPAR_COVID_19_Vaccine_AstraZeneca_05.01.2021.pdf
RE: Follow up from yesterday meeting
Commission IR 2021/111 of 29 Jan 2021
Commission IR 2021/111 of 29 Jan 2021 Regulation FD
APA AstraZeneca – 2nd instalment payment – second request for full report
APA AstraZeneca – 2nd instalment payment request – Response letter
follow-up questionnaire - sent to Astra Zeneca
Email follow-up questionnaire - sent to Astra Zeneca
skype meeting with Astra Zeneca - 14/05/2020 - vaccines
<b>BioNTech&amp;Pfizer</b>
2. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical) 07-11-2020
3. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical)09-11-2020 2
5. Draft APA negotiated between BioNTech&Pfizer and Evaluation Committee (technical) 09-11-2020
13. Follow up exploratory talks Pfizer call 08 06 2020
Tender submission (in 3 emails)
CALL FOR TENDERS SANTE/2020/C3/043 - OFFER - email 1 of 3
CALL FOR TENDERS SANTE/2020/C3/043 - OFFER - email 2 of 3
Notification Letter
Invitation to tender
Tender submission
Notification Letter
Notification Letter sent to Pfizer/BNT informing of the outcome of the award procedure
Advance purchase agreement signed by Pfizer/BNT (in 2 emails)
<b>Janssen Pharmaceutica</b>
1.Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 04-09-
2. Draft APA negotiated between J&J and the Evaluation Committee 15-09-2020

3. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 18-09-
4. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 25-09-
5. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee (technical) 28-09-
6. Draft APA negotiated between J&J and the Evaluation Committee 01-10-2020
7. Draft APA negotiated between J&J and the Evaluation Committee (technical) 02-10-2020
8. Draft APA negotiated between J&J and the Evaluation Committee (technical) 06-10-2020
1. Janssen_J&J Expression of Interest to the EC re COVID-19 vaccine
3. Janssen_J&J response to the questionnaire
4. Janssen_J&J COVID-19 vaccine proposal to the EC (1)- call 6-05-2020
5. Janssen_J&J COVID-19 vaccine proposal to the EC (2)
6. Janssen_J&J COVID-19 vaccine proposal to the EC (3) - call 10-06-2020
7. Janssen_J&J COVID-19 vaccine proposal to the EC (4)- follow up call 10-06-2020
8. Draft term sheet discussed with Janssen_J&J at the Joint Negotiation Team during the exploratory talks on 11-06-
9. Draft term sheet discussed with Janssen_J&J at the Joint Negotiation Team during the exploratory talks on 17-06-
10. Janssen_J&J COVID-19 vaccine proposal to the EC and EU4 (5)
11. Draft term sheet discussed with Janssen_J&J at the Joint Negotiation Team during the exploratory talks on 10-08-
Call for tenders SANTE/2020/C3/047 for the development, production, priority-purchasing options and supply of
CALL FOR TENDERS SANTE/2020/C3/047 - OFFER
SANTE/2020/C3/047 - Notification Letter : Call for tenders for the development, production, priority-purchasing
Notification letter: SANTE/2020/C3/047: Development, production, priority-purchasing options and supply of
Follow-up questionnaire - sent to Johnson & Johnson / Janssen
skype meeting with Johnson & Johnson / Janssen - vaccine - 06/05/2020
Report from the TC with J&J on COVID 19 Vaccine
Summary: J&J TC on COVID 19 Vaccine
[Re] Summary: J&J TC on COVID 19 Vaccine
BTO: Johnson & Johnson meeting with Martin Seychell, 11 March 2020
RE: Study: Johnson and Johnson vaccine successfully prevents COVID-19 infections in monkeys
J&J accelerates COVID-19 vaccine development (Phase 1/2a Clinical Trials in Belgium starting July 2020) and
J&J Joins Industry Partners to Launch the \$1 Billion AMR Action Fund
Johnson & Johnson announces a Lead Vaccine Candidate for COVID-19
[Re] Johnson & Johnson announces a Lead Vaccine Candidate for COVID-19
RE: J&J Announces a Lead Vaccine Candidate for COVID-19
Johnson & Johnson COVID-19 vaccine development update: launch of Phase 3 clinical trials
Johnson & Johnson COVID-19 treatment development update
1. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 29-06-2020
2. Draft APA negotiated between Moderna and the Evaluation Committee on 04.11.2020- 4 pm
3. Draft APA negotiated between Moderna and the Evaluation Committee (technical) 12-11-2020
4. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 18-11-2020
5. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 18-11-2020 2
6. Draft APA negotiated between Moderna and the Evaluation Committee on 19-11-2020
Email 6. Draft APA negotiated between Moderna and the Evaluation Committee on 19-11-2020
7. Draft APA negotiated between Moderna and the Evaluation Committee on 19-11-2020 2
8. Draft APA negotiated between Moderna and the Evaluation Committee (model annex) on 19-11-2020
9. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 21-11-2020
10. Draft APA negotiated between Moderna and the Evaluation Committee (technical) 22-11-2020 2
11. Draft APA negotiated between Moderna and the Evaluation Committee (technical) 22-11-2020
12. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 24-11-2020 1

13. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 24-11-2020 2
14. Draft APA negotiated between Moderna and the Evaluation Committee (technical) on 24-11-2020 3
Question 1 in scope of Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Answer to question 1 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Question 2 in scope of Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Questions in scope of Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Answer to question 2 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Complement Answer to question 2 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Question 3 in scope of Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Answer to question 3 - Invitation to tender for procedure SANTE/2020/C3/054 (Moderna)
Call for tenders SANTE/2020/C3/054 for the development, production, priority-purchasing options and supply of
CALL FOR TENDERS SANTE/2020/C3/054 – OFFER
SANTE/2020/C3/054 - Notification Letter : Call for tenders for the development, production, priority-purchasing
Notification letter: SANTE/2020/C3/054: Development, production, priority-purchasing options and supply of
Notification letter: SANTE/2020/C3/054: Development, production, priority-purchasing options and supply of
5. Moderna info on EMA submission timeline for mRNA1273 02-08-2020
8. Moderna draft Term Sheet discussed with the JNT (i&l clauses) 20-08-2020
7. Moderna draft Term Sheet discussed with the JNT (i clause) 14-08-2020
6. Moderna draft Term Sheet discussed with the JNT 11-08-2020
6. Moderna draft Term Sheet discussed with the JNT 11-08-2020
4. Moderna draft Term Sheet discussed with the JNT (i clause) 30-07-2020
3. Reply to Moderna proposal by the Commission (SB feedback) 22-07- 2020
2. Moderna revised proposal 10-07-2020.docx (153 KB)
1. Moderna Expression of Interest to the EC re COVID-19 vaccine 29-06-2020
Invitation to tender SANTE/2021/C3/010
Tender submission
request for clarifications and missing documents (call or tenders SANTE/2021/C3/010 )
clarifications and missing documents (call or tenders SANTE/2021/C3/010 )
RE: Meeting of the Evaluation Committee with Moderna- 12.02.2021 at 16.00
RE: Meeting of the Evaluation Committee with Moderna- today (15/02) at 21:00
Email RE: Meeting of the Evaluation Committee with Moderna- today (15/02) at 21:00
RE: SANTE/2021/C3/010- Meeting of the Evaluation Committee with Moderna - 11.02.2021
Notification Letter
Notification Letter sent to Moderna informing of the outcome of the award procedure
Meeting of the Evaluation Committee with Moderna- 12.02.2021 at 16.00

#### **CureVac**

1. Draft APA negotiated between CureVac and the Evaluation Committee on 18-09-2020
2. Draft APA negotiated between CureVac and the Evaluation Committee (technical) on 25-09-202
3. PreREADS CureVac Scientific presentation to Member States on 28-09-2020
4. CureVac Scientific presentation to Member States on 28-09-2020
5. CureVac Scientific presentation to Member States on 3-11-2020
6. Draft APA negotiated between CureVac and the Evaluation Committee on 12-11-2020
7. Draft APA negotiated between CureVac and the Evaluation Committee (technical) on 24-11-2020
1. CureVac Expression of Interest to the EC re COVID-19 vaccine- call 07-05-2020
2. CureVac Expression of Interest to the EC re COVID-19 vaccine - feedback EIB
3. CureVac - response to the questionnaire

Curevac Presentation
4. CureVac Proposal to the EC re COVID-19 vaccine
5. CureVac Proposal to the EC re COVID-19 vaccine- follow up
6. CureVac draft Term Sheet discussed with the Joint Negotiation Team (first draft )16-06-2020
7. CureVac draft Term Sheet Joint Negotiation Team comments (FR) 08-07-2020
8. CureVac draft Term Sheet Joint Negotiation Team comments (EC) 08-07-2020 2
9. CureVac draft Term Sheet discussed with the Joint Negotiation Team 28-07-2020
10. CureVac draft Term Sheet discussed with the Joint Negotiation Team on 11-08-2020
11. CureVac COVID-19 vaccine update and current data from clinical trials 17-08-2020
12. CureVac draft Term Sheet discussed with the Joint Negotiation Team (L&I clause) 17-08-2020
13. CureVac draft Term Sheet discussed with the Joint Negotiation Team 18-08-2020
14. CureVac draft Term Sheet discussed with the Joint Negotiation Team (L&I clause pre-final) 19-08-2020
15. CureVac draft Term Sheet discussed with the Joint Negotiation Team (L&I clause final) 19-08-2020
16. CureVac investigational brochure (IB) for COVID-19 vaccine
Question 1 in scope of Invitation to tender for procedure SANTE 2020/C3/049 (Curevac)
Question 2 in scope of Invitation to tender for procedure SANTE 2020/C3/049 (Curevac)
Question 3 in scope of Invitation to tender for procedure SANTE 2020/C3/049 (Curevac)
Answer to question 1 & 3 - Invitation to tender for procedure SANTE/2020/C3/054 (Curevac)
Answer to question 2 - Invitation to tender for procedure SANTE/2020/C3/054 (Curevac)
Call for tenders SANTE/2020/C3/049 for the development, production, priority-purchasing options and supply of
Tender submission (see 8 below entries - submission in 8 emails)
Call for tenders SANTE/2020/C3/049 - Offer (1)
Call for tenders SANTE/2020/C3/049 - Offer (2)
Call for tenders SANTE/2020/C3/049 - Offer (3)
Call for tenders SANTE/2020/C3/049 - Offer (4)
Call for tenders SANTE/2020/C3/049 - Offer (5)
Call for tenders SANTE/2020/C3/049 - Offer (6)
Call for tenders SANTE/2020/C3/049 - Offer (7)
Call for tenders SANTE/2020/C3/049 - Offer (8)
SANTE/2020/C3/049 - Notification Letter : Call for tenders for the development, production, priority-purchasing
Notification letter: SANTE/2020/C3/049: Development, production, priority-purchasing options and supply of
Follow-up questionnaire - sent to CureVac
skype meeting with CureVac - vaccine - 07/05/2020

#### **Sanofi – GSK**

Call for tenders SANTE/2020/C3/042 for the development, production, priority-purchasing options and supply of
CALL FOR TENDERS SANTE/2020/C3/042 – OFFER
SANTE/2020/C3/042 - Notification Letter : Call for tenders for the development, production, priority-purchasing
Notification letter: SANTE/2020/C3/042: Development, production, priority-purchasing options and supply of
1. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-20
Email 1. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-20
2. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-2020 App
Email 2. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-2020 App
3. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 03-09-20
Email 3. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 03-09-20
4. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 04-09-20

Email 4. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 04-09-20
5. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 05-09-20
6. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 10-09-20
Email 6. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 10-09-20
7. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20
8. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 2
Email 8. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 2
9. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 3
10. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 14-09-20
11. Final APA sent to Sanofi&GSK for signature 16-09-20
12. Scan of a signed version of the APA sent to Sanofi&GSK 25-09-20
13. Sanofi-GSK COVID19 vaccine - Progress report 26-10-20
Sanofi&GSK proposed options on post approval studies 08-09-20
Sanofi&GSK Scientific technical presentation Sanofi-GSK 09-09-20
Summary of the meeting with Sanofi, 26 October, 12:00 – 12:45 pm, via WebEx
1. Sanofi response to the questionnaire 19-05-20 Email
1. Sanofi response to the questionnaire 19-05-20
2. GSK response to the questionnaire 21-05-20
3. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 12-06-20
4. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 22-06-20
5. Sanofi&GSK pre reads exploratory talks 24-06-20
6. Sanofi&GSK presentation exploratory talks 25-06-20
7. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 29-06-20
Answers to your questions list – guiding you in the Term Sheet version 2
Cover Letter explaining the principles of the revised Term Sheet (version 2)
8. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 10-07-20
Email 8. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 10-07-20
9. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 22-07-20
10. Draft term sheet discussed with Sanofi&GSK at the JNT during the exploratory talks 29-07-20
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
meeting with SANOFI on APIS on 2.04 - bto
follow-up questionnaire - sent to GSK
skype meeting with GSK - 12/05/2020 - vaccines

#### NOVAVAX

Novavax exploratory talks outcome 11.12.2020
Novavax exploratory talks with JNT Indemnity Liability Comments 5.11.2020
Novavax exploratory talks with JNT 6.12.2020
Novavax exploratory talks with JNT 9.12.2020
Novavax exploratory talks with JNT 25.08.2020
Novavax exploratory talks with JNT 26.08.2020
Novavax exploratory talks with JNT Idemnification 19.09.2020
Invitation to tender SANTE/2020/C3/087
Invitation to tender Tender Specifications Vaccins COVID19
Invitation to tender Annex 6 - Financial offer

Q1 : RE: Call for tenders SANTE/2020/C3/087 for the development, production, priority-purchasing options and supply of
Answer to Q1 (part 1)
Answer to Q1 (part 2) : RE: SANTE/2020/C3/087 - question on deadline
Tender submission
Draft APA based on your tender
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 1)
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 1)
Email RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 1)
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 2)
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 2)
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 3)
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (answer 3)
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 1) - follow up
RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER (request 1) - follow up - answer
RE: CALL FOR TENDERS SANTE/2020/C3/087 - New Subcontractors
Novavax / EU Commission Draft APA 03/02/2021
Novavax / EU Commission Draft APA 14/11/2020
Novavax Investigator Brochure 06/02/2021
RE: Meeting of the Evaluation Committee with Novavax- Thursday 04.03.21 at 4.30 pm
RE: Meeting of the Evaluation Committee with Novavax- Thursday 04.03.21 at 4.30 pm_2

Register number
<a href="#">Ares(2020)6521931</a>
<a href="#">Ares(2021)1548353</a>
<a href="#">Ares(2021)1548353</a>
<a href="#">ARES(2020)6522396</a>
<a href="#">ARES(2020)6522396</a>
<a href="#">Ares(2021)1080979</a>
<a href="#">Ares(2021)1080388</a>
<a href="#">Ares(2021)1080162</a>
<a href="#">Ares(2021)1080039</a>
<a href="#">Ares(2021)1079851</a>
<a href="#">Ares(2021)1079748</a>
<a href="#">Ares(2021)1079689</a>
<a href="#">Ares(2021)1079599</a>
<a href="#">Ares(2021)1079177</a>
<a href="#">Ares(2021)1078991</a>
<a href="#">Ares(2021)1078824</a>
<a href="#">Ares(2021)1078029</a>
<a href="#">Ares(2021)1077783</a>
<a href="#">Ares(2021)1077720</a>
<a href="#">Ares(2021)1077657</a>
<a href="#">Ares(2021)1077597</a>
<a href="#">Ares(2021)1077274</a>
<a href="#">Ares(2021)1077274</a>
<a href="#">Ares(2021)1077274</a>
<a href="#">Ares(2021)1080275</a>
<a href="#">Ares(2021)1076405</a>
<a href="#">Ares(2021)1571176</a>
<a href="#">Ares(2021)1571156</a>
<a href="#">Ares(2020)6521931</a>
<a href="#">Ares(2021)1571126</a>
<a href="#">Ares(2021)1271111</a>

<a href="#">Ares(2020)7907431</a>
<a href="#">Ares(2020)7908740</a>
<a href="#">Ares(2020)7909560</a>
<a href="#">Ares(2021)659748</a>
<a href="#">Ares(2020)7910195</a>
<a href="#">Ares(2020)7910870</a>

Ares(2021)30264
Ares(2021)30582
Ares(2021)30690
Ares(2021)30943
Ares(2021)31153
Ares(2021)312429
Ares(2021)312429
Ares(2021)312429
Ares(2021)340821
Ares(2020)4344395
Ares(2021)340783
Ares(2021)340783
Ares(2021)496499
Ares(2021)496499
Ares(2021)496499
Ares(2021)282661
Ares(2021)282661
Ares(2021)930498
Ares(2021)852331
Ares(2021)852331
Ares(2020)7686288
Ares(2021)732342
Ares(2020)2765988
Ares(2020)2765989
Ares(2020)2765906
Ares(2021)100050
Ares(2021)100183
Ares(2021)100626
Ares(2021)47809
Ares(2021)340523
Ares(2021)340523
Ares(2021)340593
Ares(2020)6801133
Ares(2021)312233
Ares(2021)471003
Ares(2021)1090683
Ares(2021)1092982
Ares(2021)1366751

Ares(2021)74830
Ares(2021)106692



<a href="#">Ares(2021)75337</a>
<a href="#">Ares(2021)76546</a>
<a href="#">Ares(2021)76834</a>
<a href="#">Ares(2021)106925</a>
<a href="#">Ares(2021)107085</a>
<a href="#">Ares(2021)107537</a>
<a href="#">Ares(2021)132146</a>
<a href="#">Ares(2021)132330</a>
<a href="#">Ares(2021)132368</a>
<a href="#">Ares(2021)132455</a>
<a href="#">Ares(2021)132976</a>
<a href="#">Ares(2021)133168</a>
<a href="#">Ares(2021)133223</a>
<a href="#">Ares(2021)133506</a>
<a href="#">Ares(2021)133741</a>
<a href="#">Ares(2021)133989</a>
<a href="#">Ares(2021)312329</a>
<a href="#">Ares(2021)340694</a>
<a href="#">Ares(2020)5389787</a>
<a href="#">Ares(2021)340726</a>
<a href="#">Ares(2020)2522007</a>
<a href="#">Ares(2020)2521465</a>
<a href="#">Ares(2020)1972413</a>
<a href="#">Ares(2020)1970797</a>
<a href="#">Ares(2020)1970819</a>
<a href="#">Ares(2020)2095729</a>
<a href="#">Ares(2020)4104461</a>
<a href="#">Ares(2020)3237436</a>
<a href="#">Ares(2020)3695189</a>
<a href="#">Ares(2020)2162139</a>
<a href="#">Ares(2020)2162181</a>
<a href="#">Ares(2020)1947633</a>
<a href="#">Ares(2020)5010997</a>
<a href="#">Ares(2020)4299316</a>
<a href="#">Ares(2021)338082</a>
<a href="#">Ares(2021)338541</a>
<a href="#">Ares(2021)339263</a>
<a href="#">Ares(2021)339518</a>
<a href="#">Ares(2021)340423</a>
<a href="#">Ares(2021)340719</a>
<a href="#">Ares(2021)340719</a>
<a href="#">Ares(2021)341318</a>
<a href="#">Ares(2021)341559</a>
<a href="#">Ares(2021)341766</a>
<a href="#">Ares(2021)341980</a>
<a href="#">Ares(2021)342118</a>
<a href="#">Ares(2021)343169</a>

Ares(2021)343317
Ares(2021)343486
Ares(2020)5069122
Ares(2020)5069081
Ares(2020)5069065
Ares(2020)5069065
Ares(2020)5069108
Ares(2020)5095249
Ares(2020)5095385
Ares(2020)5095409
Ares(2021)312291
Ares(2021)340662
Ares(2020)7207031
Ares(2021)340640
Ares(2021)340640
Ares(2021)435827
Ares(2021)434268
Ares(2021)434180
Ares(2021)434093
Ares(2021)434093
Ares(2021)433869
Ares(2021)433707
Ares(2021)430505
Ares(2021)430233
Ares(2021)893598
Ares(2021)1012684
Ares(2021)1153333
Ares(2021)1255168
Ares(2021)1638774
Ares(2021)1639274
Ares(2021)1639274
Ares(2021)1639254
Ares(2021)1336686
Ares(2021)1342678
Ares(2021)1638506

Ares(2021)274633
Ares(2021)288612
Ares(2021)275043
Ares(2021)275521
Ares(2021)274831
Ares(2021)275777
Ares(2021)276026
Ares(2021)302052
Ares(2021)302551
Ares(2021)746001

Ares(2021)746001
Ares(2021)304292
Ares(2021)304832
Ares(2021)305213
Ares(2021)305545
Ares(2021)306003
Ares(2021)310065
Ares(2021)311112
Ares(2021)311541
Ares(2021)311799
Ares(2021)312173
Ares(2021)312280
Ares(2021)312597
Ares(2021)312869
Ares(2020)5095417
Ares(2020)5095266
Ares(2020)5097658
Ares(2020)5095255
Ares(2020)5095206
Ares(2021)312310
Ares(2021)399673
Ares(2021)399673
Ares(2021)402256
Ares(2021)402334
Ares(2021)402575
Ares(2021)402769
Ares(2021)403272
Ares(2021)403541
Ares(2021)403817
Ares(2020)6962203
Ares(2021)340610
Ares(2020)2524003
Ares(2020)2523066

Ares(2021)312411
Ares(2020)4206796
Ares(2020)4819456
Ares(2021)340742
Ares(2021)631289
Ares(2021)631289
Ares(2021)631900
Ares(2021)631900
Ares(2021)632544
Ares(2021)632544
Ares(2021)639004

Ares(2021)639004
Ares(2021)660367
Ares(2021)660645
Ares(2021)660645
Ares(2021)661481
Ares(2021)661630
Ares(2021)661630
Ares(2021)666517
Ares(2021)666695
Ares(2021)666857
Ares(2021)667173
Ares(2021)740978
Ares(2021)741313
Ares(2021)745642
Ares(2021)537955
Ares(2021)705386
Ares(2021)705386
Ares(2021)733401
Ares(2021)733690
Ares(2021)734569
Ares(2021)735100
Ares(2021)737035
Ares(2021)738210
Ares(2021)738210
Ares(2021)738210
Ares(2021)738991
Ares(2021)738991
Ares(2021)739448
Ares(2021)739764
Ares(2020)2074101
Ares(2020)2040853
Ares(2020)2270849
Ares(2020)2566039
Ares(2020)2565985

Ares(2021)1743132
Ares(2021)1764702
Ares(2021)1764761
Ares(2021)1764880
Ares(2021)1765007
Ares(2021)1765220
Ares(2021)1765346
Ares(2021)312276
Ares(2021)312276
Ares(2021)312276

<a href="#">Ares(2020)8014575</a>
<a href="#">Ares(2020)8014640</a>
<a href="#">Ares(2020)8014730</a>
<a href="#">Ares(2021)1559399</a>
<a href="#">Ares(2021)492534</a>
<a href="#">Ares(2021)936217</a>
<a href="#">Ares(2021)471056</a>
<a href="#">Ares(2021)471056</a>
<a href="#">Ares(2021)938164</a>
<a href="#">Ares(2021)471028</a>
<a href="#">Ares(2021)935939</a>
<a href="#">Ares(2021)471078</a>
<a href="#">Ares(2021)938280</a>
<a href="#">Ares(2021)935801</a>
<a href="#">Ares(2021)1554765</a>
<a href="#">Ares(2021)1742633</a>
<a href="#">Ares(2021)1742497</a>
<a href="#">Ares(2021)1742746</a>
<a href="#">Ares(2021)1742899</a>
<a href="#">Ares(2021)1742977</a>